FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $3.71 |
|
$7.55 | $0.23 | -20.7 |
$4.50 |
|
| AT1 | $0.02 | 0.00% | $0.05 | $0.01 |
|
||
| BB1 | $0.64 |
|
$1.11 | $0.41 |
$1.76 |
|
|
| BRN | $0.17 |
|
$0.27 | $0.13 |
|
||
| CAT | $3.16 |
|
$7.72 | $2.86 |
$5.134 |
|
|
| CBL | $0.09 | 0.00% | $0.10 | $0.03 |
|
||
| CGS | $2.73 |
|
$2.97 | $1.35 | 29.8 |
$3.20 |
|
| CMP | $0.27 |
|
$0.45 | $0.24 |
|
||
| COH | $111.32 |
|
$319.56 | $88.74 | 23.6 |
$116.028 |
|
| CSX | $0.40 | 0.00% | $0.88 | $0.32 |
|
||
| CTE | $1.06 | 0.00% | $1.30 | $0.66 |
|
||
| CU6 | $2.21 |
|
$5.87 | $1.97 |
$6.50 |
|
|
| CVB | $0.04 | 0.00% | $0.18 | $0.04 |
|
||
| EBR | $0.38 | 0.00% | $1.48 | $0.37 |
$2.235 |
|
|
| EIQ | $1.22 |
|
$1.46 | $0.17 |
$1.40 |
|
|
| EMV | $1.54 | 0.00% | $2.43 | $1.48 |
$3.15 |
|
|
| EYE | $0.12 | 0.00% | $0.21 | $0.10 |
|
||
| FPH | $32.01 |
|
$35.31 | $26.51 | 40.6 |
|
|
| IME | $0.35 |
|
$0.47 | $0.22 | 16.7 |
$0.50 |
|
| IMR | $1.89 |
|
$2.25 | $1.15 |
$2.61 |
|
|
| IPD | $0.01 | 0.00% | $0.06 | $0.01 |
$0.018 |
|
|
| LDX | $0.11 |
|
$0.33 | $0.03 |
|
||
| MX1 | $0.04 | 0.00% | $0.12 | $0.04 |
$0.15 |
|
|
| NAN | $3.19 |
|
$4.77 | $2.96 | 57.0 |
$3.80 |
|
| ONE | $0.17 | 0.00% | $0.41 | $0.16 |
$0.45 |
|
|
| PCK | $0.12 | 0.00% | $0.35 | $0.03 |
|
||
| PEB | $0.25 |
|
$0.26 | $0.08 |
|
||
| PGC | $0.14 | 0.00% | $0.41 | $0.14 | 10.8 |
$0.25 |
|
| PME | $168.90 |
|
$336.00 | $107.75 | 90.6 |
$218.667 |
|
| RAP | $0.05 | 0.00% | $0.07 | $0.03 |
|
||
| RMD | $27.55 |
|
$45.25 | $25.50 | 16.5 |
$41.143 |
|
| SHG | $0.20 | 0.00% | $0.42 | $0.19 |
|
||
| SOM | $0.55 |
|
$0.95 | $0.50 | 34.4 |
$0.99 |
|
| TRJ | $0.25 |
|
$0.97 | $0.25 | 13.5 |
$0.825 |
|
-0.27% 
21.3% Previous Stories
ResMed’s Bounce-Back Complete
Oct 29 2024
A stellar first quarter has underscored ResMed’s share price bounce-back from last year’s obesity drug panic, and perhaps put to bed the initial fear of GLP-1s
Dr Boreham’s Crucible: Pro Medicus
Sep 04 2024
The New Criterion’s Tim Boreham explains the ins and outs of one of the undisputed star performers on the ASX
Pro Medicus: Don’t Stop Me Now
Aug 20 2024
Michael Gable of Fairmont Equities reports it doesn’t look like Pro Medicus shares are in a mood to stop rising any time soon
Dr Boreham’s Crucible: Blinklab
May 20 2024
Recently ASX-listed Blinklab claims the world’s best mobile phone app for detecting autism, the New Criterion’s Tim Boreham reports
ResMed Silences The Doubters
Apr 29 2024
A forecast-beating jump in gross margins was the highlight in ResMed’s March quarter result
Dr Boreham’s Crucible: 4D Medical
Apr 23 2024
The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA
Uptrend Resumed For ResMed
Mar 19 2024
Shares in ResMed seem positioned for a new 2024 high, reports Michael Gable of Fairmont Equities
Dr Boreham’s Crucible: Cochlear
Feb 28 2024
The New Criterion’s Tim Boreham explains the business case for Cochlear
Rudi Interviewed: Ongoing Potential In Technology & Growth
Feb 19 2024
It has become the 'unofficial' tradition in recent years: an interview with Livewire Markets ahead of yet another corporate reporting…
Dr Boreham’s Crucible: Artrya
Feb 15 2024
Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains